We have recently compiled a list of 9 high-growth small-cap stocks that are profitable. CorMedix Inc. tops our list for being one of the high growth stocks.

TheFly reported on Jan. 23 that HC Wainwright cut CRMD’s price target to $13 from $18, maintaining a buy rating. The adjustment reflects updated 2026-2027 guidance related to DefenCath. The firm noted that CRMD has now entered a phase where clinical outcomes will play a greater role than commercial performance in shaping the company’s future.

Similarly, on January 21, RBC Capital cut their target price on CorMedix Inc. (NASDAQ:CRMD) to $13 from $22, while maintaining an outperform rating. The company updated its models for several biotech companies after discussions with management.

CorMedix Inc. (NASDAQ:CRMD) is a biopharmaceutical company that develops and markets therapeutic products to prevent and treat serious diseases. Its lead product, DefenCath, is an FDA-approved catheter blocking solution that reduces bloodstream infections in hemodialysis patients.

While we recognize CRMD’s potential as an investment, we believe some AI stocks offer greater upside potential and less downside risk. If you’re looking for an extremely undervalued AI stock that will also benefit significantly from Trump-era tariffs and the onshoring trend, check out our free report on the best short term AI stock.

READ THE FOLLOWING: 12 Best Multibagger Stocks to Buy Ahead of 2026 i 7 Best Rising Tech Stocks to Buy Now.

Disclosure: no.